As expected, the ACLU filed a petition asking the Supreme Court to review the Myriad case. The petitioners raise two questions in their brief.
1. Are human genes patentable?
2. Did the court of appeals err in adopting a new and inflexible rule, contrary to normal standing rules and this Court’s decision in MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007), that petitioners who have been indisputably deterred by Myriad’s “active enforcement” of its patent rights nonetheless lack standing to challenge those patents absent evidence that they have been personally and directly threatened with an infringement action?
The strange things about the petition are that the first question is the ACLU’s attempt to get cute about the case.
The second is that the petitioners won on the second question when they probably shouldn’t have. The only plaintiff to have standing saw lost his standing while the case was on appeal. The Supreme Court should probably dismiss the case as moot.
We now await Myriad’s response before seeing whether the Supreme Court will wade into this case.
A copy of the petition is available here.
December 14, 2011 at 8:47 am |
[...] Plaintiffs file petition for certiorari in AMP v. USPTO (Patent Docs) (Inventive Step) [...]
March 20, 2012 at 11:29 am |
[...] has been speculated that the Supreme Court was holding the petition for review in the Myriad gene patent case until it released this opinion in Prometheus. Perhaps the Court will GVR [...]
March 27, 2012 at 9:02 am |
[...] Supreme Court decision in Mayo v. Prometheus, the Supreme Court issued a GVR order in the Myriad gene patent case. The Court Granted the petition for certiorari, Vacated the Federal Circuit opinion, and Remanded [...]
September 28, 2012 at 8:53 am |
[...] first and third questions are the same ones that it presented in its December 2011 petition to the Supreme Court. Question 3 is difficult to understand because the plaintiffs continue to win on this question [...]